Sep 15, 2022 / 08:55AM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Excellent. Welcome to the BofA London Healthcare Conference. So my name is Geoff Meacham I'm a senior biopharma analyst here at BofA. And we're thrilled to have Amgen with us and up here on stage is Peter Griffith, CFO; and Arvind Sood, Senior Director of Investor Relations. So guys, welcome to the conference. Looking forward to the discussion.
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
Geoff, thank you. Thanks for inviting us. We're glad to be here. Thank you, Bank of America. And I'd just like to open up with a few thoughts.
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Yes, let's do that.
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
First maybe share with the group. Recall our focus on long-term growth and our sharing with the group back in February about our guidance through 2030, mid-single-digit growth, upper single-digit,
Amgen Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Sep 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers